Osteosarcoma Stem Cells Have Active Wnt/β-catenin and Overexpress SOX2 and KLF4

Journal of Cellular Physiology

Volumn 231, Issue 4, 2016, Pages 876-886

  Martins Neves, Sara R ^a,b,c,d   Corver, Willem E ^a   Paiva Oliveira, Daniela I ^b,c   van den Akker, Brendy E W M ^a   Briaire de Bruijn, Inge H ^a   Bovée, Judith V M G ^a   Gomes, Célia M F ^b,c,d   Cleton Jansen, Anne Marie ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BREAST CANCER RESISTANCE PROTEIN; KRUPPEL LIKE FACTOR 4; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR SOX2; WNT PROTEIN; KRUPPEL LIKE FACTOR; TRANSCRIPTION FACTOR SOX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STEM CELL; CARCINOGENICITY; CELL ISOLATION; CELL POPULATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SIDE POPULATION CELL; STEM CELL SELF-RENEWAL; ANIMAL; CARCINOGENESIS; CELL CLONE; CELL PROLIFERATION; EMBRYONIC STEM CELL; FIBROBLAST; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MULTICELLULAR SPHEROID; NUDE MOUSE; OSTEOBLAST; PATHOLOGY; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

ANIMALS; BETA CATENIN; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; CLONE CELLS; EMBRYONIC STEM CELLS; FIBROBLASTS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE, NUDE; NEOPLASTIC STEM CELLS; OSTEOBLASTS; OSTEOSARCOMA; PLURIPOTENT STEM CELLS; SOXB1 TRANSCRIPTION FACTORS; SPHEROIDS, CELLULAR; WNT SIGNALING PATHWAY;

EID: 84941236451     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25179     Document Type: Article

References (58)

1. Adhikari AS, Agarwal N, Wood BM, Porretta C, Ruiz B, Pochampally RR, Iwakuma T. 2010. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 70:4602-4612.
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. 2003. Prospective identification of tumorigenic breast cancer cells. P Natl Acad Sci USA 100:3983-3988.
3. Baranski Z, Booij TH, Cleton-Jansen AM, Price LS, van de Water B, Bovée JV, Hogendoorn PC, Danen EH. 2015. Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma. J Pathol 236:348-359.
4. Basu-Roy U, Seo E, Ramanathapuram L, Rapp TB, Perry JA, Orkin SH, Mansukhani A, Basilico C. 2012. SOX2 maintains self renewal of tumor-initiating cells in osteosarcomas. Oncogene 31:2270-2282.
5. Basu-Roy U, Bayin NS, Rattanakorn K, Han E, Placantonakis DG, Mansukhani A, Basilico C. 2015. SOX2 antagonizes the Hippo pathway to maintain stemness in cancer cells. Nat Commun 6:6411.
6. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, Gifford DK, Melton DA, Jaenisch R, Young RA. 2005. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122:947-956.
7. Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G, Cleton-Jansen AM. 2010. Inactive Wnt/b-catenin pathway in conventional high-grade osteosarcoma. J Pathol 220:24-33.
8. Chang CC, Shieh GS, Wu P, Lin CC, Shiau AL, Wu CL. 2008. Oct-3/4 Expression Reflects Tumor Progression and Regulates Motility of Bladder Cancer Cells. Cancer Res 68:6281-6291.
9. Cho JH, Dimri M, Dimri GP. 2013. A Positive feedback loop regulates the expression of polycomb group protein BMI1 via WNT signaling pathway. J Biol Chem 288:3406-3418.
10. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CHM, Jones DL, Visvader J, Weissman IL, Wahl GM. 2006. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66:9339-9344.
11. Cleton-Jansen AM, Anninga JK, Briaire-de Bruijn IH, Romeo S, Oosting J, Egeler RM, Gelderblom H, Taminiau AHM, Hogendoorn PCW. 2009. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. Br J Cancer 101:1909-1918.
12. Colla S, Zhan F, Xiong W, Wu X, Xu H, Stephens O, Yaccoby S, Epstein J, Barlogie B, Shaughnessy JD. 2007. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood 109:4470-4477.
13. Feng W, Gentles A, Nair RV, Huang M, Lin Y, Lee CY, Cai S, Scheeren FA, Kuo AH, Diehn M. 2014. Targeting unique metabolic properties of breast tumor initiating cells. Stem Cells 32:1734-1745.
14. Francoeur AM, Assalian A. 1996. MICROCAT: A novel cell proliferation and cytotoxicity assay based on WST-1. Biochemica 3:19-25.
15. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, Ghivizzani SC, Ignatova TN, Steindler DA. 2005. Stem-like cells in bone sarcomas: Implications for tumorigenesis. Neoplasia 7:967-976.
16. Golebiewska A, Brons NHC, Bjerkvig R, Niclou SP. 2011. Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell 8:136-147.
17. Gonçalves C, Martins-Neves SR, Paiva-Oliveira D, Oliveira VEB, Fontes-Ribeiro C, Gomes CMF. 2015. Sensitizing osteosarcoma stem cells to doxorubicin-induced apoptosis through retention of doxorubicin and modulation of apoptotic-related proteins. Life Sci 130:47-56.
18. Hauben EI, Weeden S, Pringle J, Van Marck EA, Hogendoorn PCW. 2002. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer 38:1218-1225.
19. Hughes TA, Brady HJM. 2005. E2F1 up-regulates the expression of the tumour suppressor axin2 both by activation of transcription and by mRNA stabilisation. Biochem Biophys Res Commun 329:1267-1274.
20. Jho Eh, Zhang T, Domon C, Joo CK, Freund JN, Costantini F. 2002. Wnt/b-Catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 22:1172-1183.
21. Klein MJ, Siegal GP. 2006. Osteosarcoma: Anatomic and histologic variants. Am J Clin Pathol 125:555-581.
22. Kuijjer M, Namlos H, Hauben E, Machado I, Kresse S, Serra M, Llombart-Bosch A, Hogendoorn P, Meza-Zepeda L, Myklebost O, Cleton-Jansen AM. 2011. MRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts. BMC Med Genomics 4:66.
23. Lenos K, Grawenda AM, Lodder K, Kuijjer ML, Teunisse AFAS, Repapi E, Grochola LF, Bartel F, Hogendoorn PCW, Wuerl P, Taubert H, Cleton-Jansen AM, Bond GL, Jochemsen AG. 2012. Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer. Cancer Res 72:4074-4084.
24. Lv FJ, Tuan RS, Cheung KMC, Leung VYL. 2014. Concise review: The surface markers and identity of human mesenchymal stem cells. Stem Cells 32:1408-1419.
25. Ma I, Allan A. 2011. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev Rep 7:292-306.
26. Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, Chambon P, Huber M, Hohl D, Cano A, Birchmeier W, Huelsken J. 2008. Cutaneous cancer stem cell maintenance is dependent on b-catenin signalling. Nature 452:650-653.
27. Mao J, Fan S, Ma W, Fan P, Wang B, Zhang J, Wang H, Tang B, Zhang Q, Yu X, Wang L, Song B, Li L. 2014. Roles of Wnt/b-catenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment. Cell Death Dis 5:e1039.
28. Martins-Neves S, Lopes A, do Carmo A, Paiva A, Simoes P, Abrunhosa A, Gomes C. 2012. Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line. BMC Cancer 12:139.
29. Mather JP. 2012. Concise review: Cancer stem cells: In vitro models. Stem Cells 30:95-99.
30. McQueen P, Ghaffar S, Guo Y, Rubin EM, Zi X, Hoang BH. 2011. The Wnt signaling pathway: implications for therapy in osteosarcoma. Expert Rev Anticancer Ther 11:1223-1232.
31. Mohseny AB, Machado I, Cai Y, Schaefer KL, Serra M, Hogendoorn PCW, Llombart-Bosch A, Cleton-Jansen AM. 2011. Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest 91:1195-1205.
32. Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Briaire-de Bruijn I, de Jong D, van Pel M, Cleton-Jansen AM, Hogendoorn PC. 2009. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 219:294-305.
33. Moore N, Lyle S. 2011. Quiescent, slow-cycling stem cell populations in cancer: A review of the evidence and discussion of significance. J Oncol 2011:396076-396011.
34. Moussaieff A, Kogan NM, Aberdam D. 2015. Concise reviews: Energy metabolites: Key mediators of the epigenetic state of pluripotency. Stem Cells 33:2374-80.
35. Mutsaers AJ, Walkley CR. 2014. Cells of origin in osteosarcoma: Mesenchymal stem cells or osteoblast committed cells? Bone 62:56-63.
36. Oskarsson T, Batlle E, Massagué J. 2014. Metastatic stem cells: Sources, niches, and vital pathways. Cell stem cell 14:306-321.
37. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PCW, Buerger H, Aigner T, Gabbert HE, Poremba C. 2010. Molecular characterization of commonly used cell lines for bone tumor research: A trans-European EuroBoNet effort. Genes Chromosomes Cancer 49:40-51.
38. Pahl JHW, Ruslan SE, Buddingh EP, Santos SJ, Szuhai K, Serra M, Gelderblom H, Hogendoorn PCW, Egeler RM, Schilham MW, Lankester AC. 2012. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. Clin Cancer Res 18:432-441.
39. Palorini R, Votta G, Balestrieri C, Monestiroli A, Olivieri S, Vento R, Chiaradonna F. 2014. Energy metabolism characterization of a novel cancer stem Cell-Like line 3AB-OS. J Cell Biochem 115:368-379.
40. Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K. 2010. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 16:876-887.
41. Pastrana E, Silva-Vargas V, Doetsch F. 2011. Eyes wide open: A critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 8:486-498.
42. Pattabiraman DR, Weinberg RA. 2014. Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov 13:497-512.
43. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, Hintz L, Nusse R, Weissman IL. 2003. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423:409-414.
44. Saini V, Hose CD, Monks A, Nagashima K, Han B, Newton DL, Millione A, Shah J, Hollingshead MG, Hite KM, Burkett MW, Delosh RM, Silvers TE, Scudiero DA, Shoemaker RH. 2012. Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma. PLoS ONE 7:e41401.
45. Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, Sone A, Najima Y, Takagi S, Aoki Y, Wake A, Taniguchi S, Shultz LD, Ishikawa F. 2010. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotech 28:275-280.
46. Schepers AG, Snippert HJ, Stange DE, van den Born M, van Es JH, van de Wetering M, Clevers H. 2012. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337:730-735.
47. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St.Clair R, Baljevic M, White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, Angelica M, Kemeny N, Lyden D, Rafii S. 2008. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 118:2111-2120.
48. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. 2003. Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821-5828.
49. Tang N, Song WX, Luo J, Haydon R, He TC. 2008. Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 466:2114-2130.
50. Valent P, Bonnet D, Wöhrer S, Andreeff M, Copland M, Chomienne C, Eaves C. 2013. Heterogeneity of neoplastic stem cells: Theoretical, functional, and clinical implications. Cancer Res 73:1037-1045.
51. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzmán-Ramírez N, Hamdy FC, Eaton CL, Thalmann GN, Cecchini MG, Pelger RCM, van der Pluijm G. 2010. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res 70:5163-5173.
52. van Kuppeveld FJ, van der Logt JT, Angulo AF, van Zoest MJ, Quint WG, Niesters HG, Galama JM, Melchers WJ. 1992. Genus and species-specific identification of mycoplasmas by 16S rRNA amplification. Appl Environ Microbiol 58:2606-2615.
53. Wang L, Park P, Lin CY. 2009. Characterization of stem cell attributes in human osteosarcoma cell lines. Cancer Biol Ther 8:543-552.
54. Wang L, Park P, Zhang H, La Marca F, Lin CY. 2011. Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity. Int J Cancer 128:294-303.
55. Wei Z, Yang Y, Zhang P, Andrianakos R, Hasegawa K, Lyu J, Chen X, Bai G, Liu C, Pera M, Lu W. 2009. Klf4 interacts directly with Oct4 and SOX2 to promote reprogramming. Stem Cells 27:2969-2978.
56. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DAH, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA. 2010. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102:1555-1577.
57. Wu C, Wei Q, Utomo V, Nadesan P, Whetstone H, Kandel R, Wunder JS, Alman BA. 2007. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res 67:8216-8222.
58. Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, Lagoo A, Reya T. 2007. Loss of β-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer cell 12:528-541.